nach oben

memo - Magazine of European Medical Oncology

Tipp

Revival of anti-angiogenic therapies in cancer

News from an old therapeutic concept—part 2

verfasst von: Andreas Pircher, MD PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Referring to the last issue presenting state of the art reviews [ 1] on the use of anti-angiogenic drugs in colorectal [ 2], urological [ 3, 4] and breast cancer [ 5] as well as in angiosarcomas [ 6], the present issue extends the topic to additional angiogenesis-dependent malignancies. Hereby, ovarian cancer and non-small cell lung cancer (NSCLC) represent two highly vascularized tumor entities where anti-angiogenic therapies form a robust backbone for the treatment of advanced stage disease mostly in combination with chemotherapy or newer therapeutic therapies. …

Nächster Artikel Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes

Pircher A. Revival of anti-angiogenic therapies in cancer—news on an old therapeutic concept. Memo. 2017;10(4):185–6. CrossRef

Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. Memo. 2017;10(4):213–7. CrossRef

Haidl F, Pfister D, Heidenreich A, Heidegger I. Antiangiogenic therapies in urogenital malignancies. Memo. 2017;10(4):202–5. CrossRefPubMedPubMedCentral

Pichler R, Heidegger I. Novel concepts of antiangiogenic therapies in metastatic renal cell cancer. Memo. 2017;10(4):206–12. CrossRefPubMedPubMedCentral

Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer. Memo. 2017;10(4):194–201. CrossRefPubMedPubMedCentral

Young RJ, Woll PJ. Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update. Memo. 2017;10(4):190–3. CrossRefPubMedPubMedCentral

Vanderstichele A, Olbrecht S, Vergote I. Antiangiogenic therapies in ovarian cancer. Memo. 2018; https://doi.org/10.1007/s12254-018-0392-2.

Daher S, Bar J. Targeting angiogenesis in lung cancer. Memo. 2018; https://doi.org/10.1007/s12254-018-0391-3.

Berghoff AS, Preusser M. Anti-angiogenic therapies in brain metastases. Memo. 2018; https://doi.org/10.1007/s12254-018-0384-2.

Titel: Revival of anti-angiogenic therapies in cancer
News from an old therapeutic concept—part 2
verfasst von: Andreas Pircher, MD PhD
Publikationsdatum: 27.02.2018
Verlag: Springer Vienna
Schlagwort: Onkologie
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0394-0

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Revival of anti-angiogenic therapies in cancer

News from an old therapeutic concept—part 2

Excerpt

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

In need of special care: adolescent and young adult patients with cancer

My burning issues in TKI therapy and treatment-free remission in CML

Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer

Antiangiogenic therapies in ovarian cancer

Novel guidelines on surveillance for breast cancer, cardiomyopathy, male gonadotoxicity, and premature ovarian insufficiency from the PanCare and International Guideline Harmonization Group on long-term follow-up after cancer in childhood